Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956609 | 0.95 | ROCK2 (0.50) | ROCK2POLBKDM1ARCOR1MAOA | |
| SCHEMBL5956664 | 0.95 | ROCK2 (0.50) | ROCK2POLBKDM1ARCOR1MAOA | |
| SCHEMBL5956550 | 0.95 | ROCK2 (0.50) | ROCK2POLBKDM1ARCOR1MAOA | |
| SCHEMBL5956624 | 0.92 | POLB (0.47) | ROCK2POLBKDM1ARCOR1MAOA | |
| SCHEMBL5956900 | 0.86 | ALDH1A1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL5956777 | 0.84 | POLB (0.51) | ROCK2POLBKDM1ARCOR1MAOA | |
| SCHEMBL5956937 | 0.84 | CTSK (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5956646 | 0.81 | POLB (0.51) | ROCK2POLBKDM1ARCOR1MAOA | |
| SCHEMBL5956725 | 0.81 | POLB (0.51) | ROCK2POLBKDM1ARCOR1MAOA | |
| SCHEMBL5956707 | 0.80 | ALDH1A1 (0.45) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885POLB 3152/4885KDM1A 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.